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Background. Chronic renal allograft rejection is characterized
histologically by transplantation-associated arteriosclerosis and
glomerulosclerosis (Tx-AA and Tx-AGS). Recent studies in ani-
mal models implicate the mitogenic and pressor actions of
endothelin-1 (ET-1) in Tx-AA. In humans, however, a link
between elevated ET-1 secretion and Tx-AA or Tx-AGS remains
unclear. In this study we analyzed expression of ET-1 in the
vasculature of renal transplant patients with chronic or acute
rejection and in normal controls.
Methods. Renal vascular and glomerular ET-1 was assessed by
immunohistochemistry in 12 patients with clinically and histolog-
ically defined chronic rejection, in 11 patients with acute rejection,
and in 5 normal kidneys. ET-1 staining was also correlated with
various clinical parameters and with a morphometric index of
neointima formation. ET-1 secretion was measured by ELISA in
cultured human vascular cell types treated with T cell- and
macrophage-associated cytokines.
Results. We found that renal allografts with chronic rejection
and Tx-AA expressed 6.1-fold more ET-1 in the vasculature
relative to allografts with acute rejection or to normal kidneys
(P , 0.01). In Tx-AA, ET-1 was detected predominantly in the
neointima, which contained mostly endothelial cells and smooth
muscle cells. A strong positive correlation (r 5 0.82, P , 0.01) was
observed between vascular ET-1 peptide expression and hyper-
tension in patients with chronic rejection. We also showed that
macrophage-associated cytokines, but not T cell-associated cyto-
kines, stimulated ET-1 secretion in human endothelial cells,
vascular smooth muscle and mesangial cells.
Conclusions. These results demonstrate that elevated ET-1 in
the neointima is associated with Tx-AA and chronic rejection. In
addition, these results point to an important role for endothelial
dysfunction in chronic renal allograft rejection.
Chronic rejection and transplantation-associated vascu-
lar disease are the major obstacles to long-term survival of
renal and other solid organ allografts [1–7]. In renal
allografts, two major forms of transplantation-associated
vascular disease are observed: (i) arteriosclerosis of arteries
and arterioles (Tx-AA, transplantation-associated arterio-
sclerosis or vasculopathy), and (ii) sclerosis of the glomer-
ular microvasculature (Tx-AGS, transplantation-associated
glomerulosclerosis). Concentric formation of an occlusive
neointima is the hallmark of Tx-AA, whereas Tx-AGS is
characterized principally by expansion of the mesangial
matrix, proliferation of intrinsic mesangial cells, and the
resultant loss of functioning capillaries [4, 5, 8]. The
pathogenesis of Tx-AA and Tx-AGS remains unclear,
although both immune [1, 9, 10] and non-immune [6, 11]
mechanisms undoubtedly contribute. In particular, the role
of endothelial inflammation and endothelial-derived medi-
ators is poorly understood [1, 3].
One such endothelial-derived mediator is endothelin-1
(ET-1), a potent vasoconstrictor and vascular growth factor
[reviewed in 3, 12, 13]. In a rat model of chronic rejection
in cardiac allografts, the vascular neointima secretes mark-
edly more ET-1 than the vasculature of isograft controls
[14, 15]. ET-1 is also elevated at fibrotic sites associated
with interstitial rejection and ischemic myocardial damage.
In a rat model of chronic renal allograft rejection, total
kidney ET-1 mRNA is elevated shortly after early revers-
ible acute rejection episodes but before development of
proteinuria and glomerulosclerosis that presage chronic
rejection [16, 17]. Although the cellular source of ET-1
secretion has not been identified in these previous studies,
the increase in ET-1 mRNA immediately following the
burst in cytokine expression from T cells and macrophages
suggests that cytokines mediate the increase in ET-1 gene
expression [16–18]. Several studies in humans reveal in-
creased ET-1 expression in heart, lung, and kidney allo-
grafts [19–25], and one study clearly documents elevated
ET-1 in the neointima of cardiac allograft patients with
Tx-AA [25]. Collectively, these results suggest that the
vasoconstrictor and mitogenic functions of ET-1 might
contribute to the pathogenesis of transplantation-associ-
ated vascular disease in renal allografts [3].
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As a first step towards understanding the role of ET-1 in
Tx-AA of human renal allografts, in this study we asked
whether ET-1 is elevated in the vasculature of Tx-AA in
chronic renal allograft rejection. We report here that, in
patients undergoing chronic renal allograft rejection, vas-
cular and glomerular expression of ET-1 is elevated com-
pared to patients with acute rejection and to normal
controls. ET-1 expression correlated with neointima forma-
tion in Tx-AA. These results suggest possible autocrine
and/or paracrine actions for ET-1 in the pathogenesis of
Tx-AA and Tx-AGS. Moreover, these findings point to an
important role for endothelial dysfunction in transplanta-
tion-associated vascular disease in the kidney.
METHODS
Patients and controls
We studied 23 renal transplant recipients with clinical
and histologic evidence of actue (N 5 11) or chronic (N 5
12) allograft rejection. All studies were approved by the
Institutional Review Board, University Hospitals of Cleve-
land. Characteristics of subjects at the time of tissue
recovery are summarized in Tables 1 and 2. Chronic
rejection was considered clinically in patients who had been
transplanted for at least one year and who exhibited
proteinuria (.500 mg/day) and/or a slow, steady increase in
serum creatinine concentration from a value obtained six
months post-transplant. Acute rejection was considered
clinically when patients exhibited a rise in serum creatinine
concentration of at least 30% above baseline over a period
of less than three months. In each patient the severity of
systemic hypertension was scored as follows: 0 5 no
hypertension, no antihypertensive medication; I 5 normal
blood pressure on antihypertensive medication; II 5 above
normal blood pressure on antihypertensive medications;
and III 5 above normal blood pressure on more than two
antihypertensive medications.
Kidney tissue was obtained by biopsy or nephrectomy
and immediately processed for immunohistochemistry as
described below. All tissue samples were blindly graded for
chronic or acute renal allograft rejection using the Banff
criteria [26]. Patients with clinically diagnosed chronic
rejection but with histologic evidence of both acute and
chronic rejection were categorized in the chronic rejection
group. The vasculature of each sample was graded for
Tx-AA using the morphological scale of Russell and co-
workers [27]. Normal human kidneys (N 5 4), surgically
excised due to localized neoplasm, were obtained from the
National Cancer Institute Cooperative Human Tissue Net-
work at Case Western Reserve University. All tissue was
distant from the neoplasm and macroscopically normal. At
the time of excision, patients had normal serum creatinine
concentrations and normal blood pressures.
Immunohistochemical analysis
Small blocks of fixed (10% buffered formalin) kidney
were embedded in paraffin and 5 mm sections were cut.
De-paraffinized sections were washed in Dulbecco’s phos-
phate buffered saline (DPBS) and incubated with 1.5%
H2O2 in methanol to block endogenous peroxidase activity
followed by five DPBS washes. To block non-specific
binding, sections were incubated with 10% normal goat
serum (NGS). Rabbit polyclonal antisera raised against
human ET-1 (1:200 to 1:400 in DPBS/1.0% NGS;
#RIN6901; Peninsula Labs, Belmont, CA, USA) or a
monoclonal antibody against endothelin-1 (1:100 dilution;
QED Bioscience, San Diego, CA, USA) were added in a
humidity chamber at room temperature for one hour. Cross
reactivities of the polyclonal antisera were: ET-1, 100%;
ET-2, 7%; ET-3, 7%; proET-1, 17%. The monoclonal
antibody recognized only ET-1. Both antibodies gave es-
sentially identical results. For negative controls primary
antibody was replaced with non-immune serum at the same
concentration of IgG. Antibodies were then localized with
a peroxidase-labeled F(ab9)2 fragment goat anti-rabbit (or
mouse) IgG at 1:200 (Kierkegaard and Perry Laboratories,
Inc., Gaithersburg, MD, USA). The sections were finally
treated for five minutes with a freshly prepared diamino-
benzidine substrate solution with enhancement and washed
in tap water. After lightly counterstaining in methyl green,
the sections were dehydrated in ethanol, cleared in xylene,
and mounted in Eukitt (Calibrated Instruments Inc., Haw-
thorne, NY, USA). Photomicrographs were exposed and
developed so that semiquantitative comparison of relative
staining intensity was possible, and densitometric analysis
of ET-1 immunoreactivity was performed using NIH Image
v. 5.1 for the Macintosh.
In other experiments the sections were stained with the
following primary antibodies to identify specific cell types
within the neointima: polyclonal anti-Factor VIII (1:100,
A0082; Dako, Carpinteria, CA, USA) for endothelial cells;
monoclonal anti-a-smooth muscle actin (1:50, clone 1A4;
Sigma Chemical Co., St. Louis, MO, USA) for vascular
smooth muscle cells; polyclonal anti-CD3 (1:100, A0452;
Dako) for T cells; and monoclonal anti-CD68 (1:75,
M0876; Dako) for monocytes/macrophages. The antibodies
were then detected and the tissue processed exactly as
described above.
Cell culture
Human vascular cells were propagated in culture for
measurements of cytokine-stimulated ET-1 secretion. Hu-
man umbilical vein endothelial cell (HUVEC) lines were
obtained from the American Type Culture Collection
(ATCC, ECV 304) and cultured in Medium 199 with 10%
fetal bovine serum, 100 units/ml penicillin, and 100 mg/ml
streptomycin [28]. Human aortic vascular smooth muscle
cell strains from the ATCC (CRL-1999) were cultured in
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F12K medium with 10% fetal bovine serum, 100 units/ml
penicillin, 100 mg/ml streptomycin, 10 mg/ml each of insulin
and transferrin, 10 ng/ml selenite, 30 mg/ml endothelial
growth supplement, 50 mg/ml ascorbic acid, 2 mM glu-
tamine, 10 mM HEPES, and 10 mM TES [(N-tris) hy-
droxymethylmehtyl-2-aminoethanesulfonic acid]. Mesan-
gial cell strains from human kidney were isolated and
characterized as previously reported by Schultz et al [29].
Cells were maintained in RPMI 1640 medium supple-
mented with 17% fetal bovine serum, 100 units/ml penicil-
lin, 100 mg/ml streptomycin, 5 mg/ml each of insulin and
transferrin, and 5 ng/ml selenite at 37°C in 5% CO2
incubator. Characterization was performed by phase con-
trast microscopy and by immunostaining for intermediate
filaments and surface antigens as described [29]. Briefly,
cells were positive for desmin, vimentin and myosin, but did
not stain for factor VIII, keratin, or common leukocyte
antigen.
Measurements of endothelin-1 secretion
Confluent cells in 12-well plates were made quiescent for
24 hours in DMEM/0.1% fetal bovine serum. Prior to
stimulation with cytokines (R&D Systems, Minneapolis,
MN, USA), the quiescent media was changed to Hank’s
balanced salt solution (without phenol red) with 25 mM
HEPES and 0.1% fetal bovine serum. One milliliter of
culture supernatant was extracted with 1.5 ml acetone:1 M
HCl:water (40:1:5 vol/vol) and centrifuged at 4°C for 20
minutes at 1,200 3 g. The supernatant was dried down,
reconstituted in 250 ml, neutralized to pH 7.0, and assayed
immediately for ET-1. Immunoreactive ET-1 was measured
in 100 ml aliquots using a double antibody sandwich
Table 1. Patients with chronic renal allograft rejection
# Age, years/sex
Kidney
diseasea
Graft duration
at biopsy,
yearsb
Tx
typec
Plasma
Creatinine
mg/dl
HTN
scored
Chronic Banff
Scoree
1 40 M Congen 20 Cad 6.9 I III, 3, 2
2 19 F Congen 3 LR 3.1 0 III, 2, 2
3 66 F Calculi 5 Cad on dialysis I III, 3, 3
4 36 F Diabetes 11 Cad 4.2 II III, 2, 3
5 39 M GN 6 Cad 12.9 III III, 3, 3
6 61 M GN 6 Cad 6.5 II III, 1, 3
7 58 M Diabetes 2.5 Cad 4.3 0 II, 2, 2
8 35 M GN 10 Cad 7.8 I III, 1, 3
9 33 F HTN 3 Cad 9.0 II III, 2, 3
10 36 F Diabetes 6 Cad 8.2 I III, 3, 3
11 41 M GN 5 Cad 4.1 II II, 2, 3
12 26 F GN 2.5 LUR 4.3 II II, 1, 1
a Kidney disease: Congen, congenital or kidney agenesis; GN, glomerulonephritis; HTN, hypertension
b Refers to years post-transplant at time of biopsy
c Transplant type: Cad, cadaveric; LR, living related donor; LUR, living unrelated
d Defined in the Methods section
e Chronic vascular and chronic glomerular scores are from Solez et al, Kidney International 44:411–422, 1993
Table 2. Patients with acute rejection
# Age, years/sex
Kidney
diseasea
Graft duration
at biopsy,
yearsb
Tx
typec
Plasma
creatinine
mg/dl
HTN
scored
Acute Banff
Scoree
1 18 F Congen 0.5 LR 1.0 I II
2 58 F Unknown 0.4 LR 7.1 0 II
3 54 M HTN 0.5 LR 5.6 II I
4 47 F Diabetes 5.5 Cad 2.3 0 I
5 31 F Congen 0.4 LR 2.2 I I
6 29 F Congen 1.2 LR 3.5 II I
7 40 F Diabetes 0.1 Cad 5.4 II II
8 63 M Diabetes 0.3 Cad 13.5 0 II
9 57 F HTN 0.4 Cad 3.4 I I
10 11 M Congen 0.1 Cad 2.8 I II
11 45 M Diabetes 0.2 Cad 8.1 II II
a Kidney disease: Congen, congenital or kidney agenesis; GN, glomerulonephritis; HTN, hypertension
b Refers to years post-transplant at time of biopsy
c Transplant type: Cad, cadaveric; LR, living related donor; LUR, living unrelated
d Defined in the Methods section
e Chronic vascular and chronic glomerular scores are from Solez et al, Kidney International 44:411–422, 1993
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enzyme-linked immunosorbent assay (R&D Systems) with
minor modifications. Cross reactivity in the ELISA assay
were bigET-1 , 1.0%, ET-2 , 45%, and ET-3 , 14%.
Absorbance readings from a media blank were subtracted
from the experimental values. All assays were done in
duplicate.
Data analysis
Statistical significance for densitometric analysis of ET-1
staining was calculated by an unpaired t-test. For analysis of
ET-1 secretion, statistical significance was calculated by a
paired t-test in which repeated experiments run at different
times were compared with their own control. Data pre-
sented are mean 6 SEM normalized to the intra-experimen-
tal control value. Statistical analysis was performed using
InStat for the Macintosh (Version 2.0; GraphPad Software,
San Diego, CA, USA).
RESULTS
Vascular expression of ET-1 is elevated in Tx-AA
Table 1 summarizes the characteristics of the six male
and six female subjects with chronic renal allograft rejec-
tion at the time tissue was obtained. Table 2 summarizes
the same information for the four male and seven female
subjects with acute rejection. Subjects were similar in age
(40 6 14 years and 41 6 17, respectively, mean 6 SD) and
in racial distribution. The average duration of graft survival
was 6.7 6 5.0 years for subjects with chronic rejection
compared to 0.8 6 1.5 years for subjects with acute
Fig. 1. Elevated endothelin-1 (ET-1) peptide
levels in the renal vascular neointima of
patients with transplant-associated
arteriosclerosis (Tx-AA) and chronic rejection.
(A) Immunohistochemical localization of ET-1
in the neointima (arrowhead) and adventitia
(arrowhead) of a small artery with Tx-AA. The
majority of arterial vessels analyzed had
elevated ET-1 only in the neointima. (B) ET-1
staining localizes primarily to the endothelium
(arrowheads) in an arcuate artery from normal
kidney.
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rejection. Average values for serum creatinine concentra-
tion were similar in both groups (6.5 6 2.9 mg/dl and 5.0 6
3.6, respectively).
To determine whether ET-1 secretion was elevated in the
vasculature of subjects with Tx-AA, ET-1 was analyzed by
immunohistochemistry in renal tissue from the 12 patients
with chronic rejection. ET-1 staining in a representative
artery with Tx-AA and neointima formation is illustrated in
the photomicrograph in Figure 1A. ET-1 staining was
abundant in the neointima (arrowhead, Fig. 1A), particu-
larly in the endothelium and in distinct underlying cells.
ET-1 staining in the neointima was reproducibly observed
in both arteries and arterioles with Tx-AA and neointima
formation. ET-1 staining in Tx-AA was occasionally found
in the adventitia (arrowhead, Fig. 1A), but adventicial ET-1
was not present in all vessels that contained neointimal
ET-1. The pattern of ET-1 staining in Tx-AA contrasts with
the primarily endothelial localization of ET-1 in the arcuate
artery and in other renal vessels from normal subjects
(arrowheads, Fig. 1B). In renal veins of subjects with
chronic rejection, ET-1 localized exclusively to the endo-
thelium and was indistinguishable from ET-1 staining in
renal veins from normal subjects (data not shown). To
assess continuity of the endothelium in Tx-AA, sections
were also stained with a polyclonal antibody that recognizes
Factor VIII, and in all cases the endothelium was appar-
ently intact in Tx-AA (Fig. 1C). In addition, staining of
renal sections from chronically rejecting kidney with non-
immune antisera demonstrated that the immunhistochemi-
cal analysis was highly specific (Fig. 1D). Taken together,
these results demonstrate that ET-1 secretion is prominent
in the neointima (and sometimes in the adventitia) of
vessels with Tx-AA.
To determine whether elevated vascular secretion of
Fig. 1. Cont’d. (C) Staining for Factor VIII in
vessels with Tx-AA demonstrated that the
endothelium was intact. (D) Immunohisto-
chemical staining with non-immune serum in a
vessel with Tx-AA. Magnification 31400.
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ET-1 was specific for patients with chronic rejection, we
examined vascular ET-1 secretion in 11 subjects with acute
rejection lacking pathological evidence of Tx-AA (Table 2).
ET-1 staining localized to the intima and was essentially
normal in renal vessels of patients undergoing acute rejec-
tion (data not shown). A semiquantitative densitometric
analysis of vascular ET-1 staining revealed that ET-1
secretion was unchanged in acute rejection but was ele-
vated 6.1-fold in chronic rejection compared to vessels of
normal subjects (Fig. 2). In fact, 2 of 11 subjects with acute
rejection actually had lower vascular ET-1 than observed in
normal vessels. These results suggest that elevated vascular
ET-1 secretion is specific for Tx-AA and chronic rejection
and not the result of generalized aberrant expression of
ET-1 in donor renal vessels.
We next analyzed the relationship between vascular
ET-1 levels in Tx-AA and various clinical and pathological
parameters measured in these subjects (that is, Russell
index of Tx-AA and parameters listed in Table 1). A
positive correlation was observed between vascular ET-1
expression and the Russell morphometric index of Tx-AA
(Fig. 3, r 5 0.78, P , 0.01), which primarily grades the
extent of neointima formation. An index of hypertension
(Table 1) in patients with chronic rejection also correlated
with ET-1 expression (Fig. 3; r 5 0.82, P , 0.01). Strong
correlations were not observed between serum creatinine
concentration, initial type of kidney disease, age, sex, or
years of graft survival.
Multiple cell types in the neointima stain positively for
ET-1
We next asked what cell types in the neointima of Tx-AA
stain positively for ET-1. Previous studies in animal models
and humans have reported that the neointima of Tx-AA
contains variable numbers of endothelial cells, vascular
smooth muscle cells, macrophages, and T cells [1, 10].
Sufficient tissue existed from three patients with chronic
rejection to stain serial sections for ET-1 and the following
cell type-specific markers: Factor VIII (endothelial cells),
smooth muscle a-actin (vascular smooth muscle), CD-68
(macrophage/monocyte), and CD-3 (T cells). A semiquan-
titative analysis was then performed in which the total
number of a specific cell type was calculated as a percent-
age of all cells in the vessel, and these cells were further
scored for ET-1 staining. As shown in Table 3, endothelial
cells comprised 8% of neointimal cells and always stained
positive for ET-1. As shown above (Fig. 1C), the endothe-
lium is largely intact in Tx-AA. As expected, vascular
smooth muscle cells were the most populous cell type (that
is, 75%) but only 35% stained positive for ET-1. Infiltrating
macrophages/monocytes and T cells were also present (8
and 3%, respectively; Table 3), but positive ET-1 staining
was detected in only 31% of macrophage/monocytes and
was never observed in T cells. Approximately 6% of cells
failed to stain for any cell type-specific marker and were
thus unidentified; however, these cells were not ET-1-
positive. Collectively, these results suggest that nearly all
endothelial cells and approximately one-third of smooth
muscle cells and macrophage/monocytes elaborate ET-1 in
the neointima. Considerable heterogeneity clearly exists in
the propensity of smooth muscle cells and macrophage/
monocytes to elaborate ET-1.
Macrophage-associated cytokines stimulate ET-1
secretion
To gain insight into possible stimuli of ET-1 secretion in
Tx-AA, we tested the ability of alloreactive cytokines to
up-regulate ET-1 peptide secretion in cultured endothelial
cells from human umbilical veins. We chose to test cyto-
kines that have previously been shown by Nadeua and
coworkers [16, 18] to be elevated shortly before the burst of
ET-1 secretion in a rat model of chronic renal allograft
rejection: T cell (IL-2, IL-4, IFNg)- and macrophage
(IL-1b, IL-6, and TNF-a)-associated cytokines. We ob-
served that IL-1b was a potent stimulus of ET-1 secretion
with significant stimulation occurring at three hours and
continuing in a time-dependent manner at five hours (Fig.
4 and Table 4). IL-6 and TNF-a stimulated a modest and
slower increase in ET-1 secretion at five hours (Fig. 4 and
Table 4). Interestingly, the T cell-associated cytokines IL-2,
IL-4, and IFNg failed to stimulate ET-1 secretion (Table
4). Twenty-four hour incubations with IL-2, IL-4, and IFNg
failed to significantly elevate ET-1 above basal levels in
HUVEC and vascular smooth muscle cells (N 5 3 in
duplicate, data not shown). We used 12–0–tetradecanoyl
phorbol 13 acetate (TPA) as a positive control in each
experiment because previous experiments have shown that
protein kinase C is a potent stimulus of ET-1 secretion, and
in all experiments TPA stimulated an approximately three-
fold increase in ET-1 secretion (Fig. 4 and Table 4).
Fig. 2. Immunoreactive ET-1 in the vasculature was elevated in chronic
rejection but essentially normal in acute rejection. The density of vascular
ET-1 staining in representative sections from 12 patients with chronic
rejection and 11 patients with acute rejection was analyzed using NIH
Image. Data are mean 6 SEM in relative densitometric units.
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Because the immunohistochemical results presented
above demonstrate that some vascular smooth muscle cells
stain positive for ET-1 in Tx-AA, we also asked whether T
cell- or macrophage-associated cytokines would stimulate
ET-1 secretion in these cells in culture. Only IL-1b and
IL-6 significantly elevated ET-1 secretion in cultured hu-
man vascular smooth muscle cells (Table 4); however, as
expected, levels of ET-1 secretion in vascular smooth
muscle were always significantly less than in endothelial
cells. TNFa and the T cell-derived cytokines did not elevate
ET-1 secretion even though TPA as a positive control
always stimulated ET-1 secretion. These experiments sug-
gest that macrophage-associated cytokines such as IL-1b,
IL-6, and TNFa might be important stimuli of ET-1
secretion in Tx-AA.
Glomerular expression of ET-1 is elevated in Tx-AGS
Because glomeruli and mesangial cells are biological
targets for ET-1, we investigated whether glomerular stain-
ing for ET-1 was elevated in Tx-AGS. Focal and segmental
Fig. 3. Vascular expression of ET-1 in Tx-AA correlates with the Russell morphometric index of Tx-AA and with an index of hypertension.
Densitometric values of ET-1 expression in the vasculature of patients with Tx-AA were correlated with a morphometric index that grades the severity
of Tx-AA (A) and with an index that assess the severity of hypertension (B; Tables 1 and 2). Significant correlations (P , 0.01) were observed in both
analyses. In A, r 5 0.78, and in B, r 5 0.82.
Fig. 4. Interleukin-1b (IL-1b) stimulates secretion of ET-1 from human
umbilical vein endothelial cells (HUVEC) in culture. HUVEC cells in
serum-free media were stimulated for the times indicated with 10 ng/ml
IL-1b, 10 ng/ml IL-6, or 100 nM TPA. The supernatants were then
collected and extracted ET-1 was measured by ELISA. Controls were
treated with media alone. Data are mean 6 SEM from three independent
experiments in duplicate. Symbols are: () TPA; (F) IL-1b; (E) IL-6; (f)
control; **P , 0.01; *P , 0.05.
Table 3. Composition of cells in the neointima and percentage of these cells elaborating ET-1 immunoreactivity
Immunohistochemical
Marker Cell type
% of Total cells
in neointima
% of Cell type
with ET-1
immunoreactivity
Factor VIII Endothelial cells 8 100
Smooth muscle a-actin Vascular smooth muscle 75 35
CD-68 Macrophage/monocyte 8 31
CD-3 T Cells 3 0
None detected Other 6 0
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ET-1 staining was observed in patients (Table 1) with
chronic rejection and Tx-AGS (arrows, Fig. 5A). Although
it was difficult to establish the precise cellular pattern of
ET-1 staining in Tx-AGS, it clearly contrasted with the
primarily segmental endothelial pattern of staining ob-
served in normal human kidney (arrows, Fig. 5B). Semi-
quantitative analysis of glomerular ET-1 staining in Tx-
AGS revealed a 2.7-fold increase (Fig. 6). In patients with
acute rejection (Table 2), glomerular ET-1 staining was
essentially normal or slightly depressed (Fig. 6). It is also
important to note that the glomerular endothelium was
largely intact in Tx-AGS and stained uniformly for Factor
VIII (arrows, Fig. 5C). Experiments with non-immune
serum confirmed that glomerular immunohistochemical
staining for ET-1 in Tx-AGS was highly specific (Fig. 5D).
The same T cell- and macrophage-associated cytokines
tested earlier in endothelial and vascular smooth muscle
cell cultures were also tested for their ability to stimulate
ET-1 secretion in cultured human mesangial cells. As
before, only the macrophage-associated cytokines IL-1b
and IL-6 stimulated ET-1 secretion, and in mesangial cells
IL-6 was significantly more potent that IL-1b (Table 4).
DISCUSSION
The question addressed by the present study was whether
ET-1 secretion is elevated in the vasculature of patients
with Tx-AA and chronic renal allograft rejection. The main
finding is that ET-1 secretion is elevated in the vascular
neointima in Tx-AA and chronic rejection compared with
the vasculature in acute rejection or normal kidney. Ele-
vated levels of ET-1, a vasoconstrictor peptide with potent
mitogenic actions, might contribute to the fibroproliferative
neointima that characterizes Tx-AA in chronic renal allo-
graft rejection.
ET-1 is elevated in the neointima of Tx-AA
Our immunohistochemical analysis of vascular ET-1 in
patients with Tx-AA and chronic rejection showed that
ET-1 staining was elevated 6.1-fold over vascular staining in
an age-matched population of patients with acute rejection
and without pathological evidence of Tx-AA. ET-1 in
Tx-AA was mostly localized to the neointima and was only
rarely demonstrated in the medial layer. In some vessels
significant immunoreactive ET-1 was also localized in the
adventitia. Focal inflammation in the adventitia has previ-
ously been described in Tx-AA and might account for the
occasionally dense staining for ET-1 we observed. It is
important to note, however, that the most common finding
was elevated ET-1 in the neointima as contrasted with the
primarily intimal expression of ET-1 in renal vessels from
patients with acute rejection and in normal kidney. It is also
striking that renal venous expression of ET-1 was appar-
ently unchanged in patients with chronic rejection, suggest-
ing that the preproET-1 gene is differentially regulated in
arteries and veins in Tx-AA.
We also determined that elevated ET-1 in Tx-AA was
not a non-specific consequence of transplantation as vas-
cular ET-1 was unchanged in patients undergoing acute
rejection. Our finding of normal or slightly lower vascular
ET-1 in acute rejection agrees with an earlier study by
Watschinger and coworkers in which ET-1 levels were not
elevated in renal transplant patients with acute rejection
compared with normal kidney [21]. Although vascular ET-1
is not apparently elevated in renal transplants with acute
rejection, it seems quite likely that ET-1 may be elevated
immediately following transplantation where it might con-
tribute to renal damage subsequent to ischemia and/or
reperfusion. We did not have the opportunity to analyze
ET-1 levels in renal tissue immediately following transplan-
tation, but rat models of cardiac and renal transplantation
show a rapid, transient burst of ET-1 immediately following
surgery [14, 17]. In addition, ET-1 is well-known to increase
in response to renal ischemia [12, 13]. However, our
present results and previous studies in animals [14–17] and
humans [19, 25] suggest that the increase in vascular ET-1
that occurs in chronic rejection and Tx-AA is sustained.
Two independent studies of patients with cardiac allografts
clearly show elevated neointimal ET-1 in chronic rejection
and Tx-AA [19, 25]. The pattern of neointimal ET-1 in
these studies is quite similar to our localization of ET-1 in
renal Tx-AA. Studies in rats with chronic rejection of
cardiac [14, 15] and renal [16, 17] allografts also document
selective and sustained elevation of ET-1 in chronic rejec-
tion. ET-1 was not localized in the renal studies [16, 17], but
ET-1 staining in the cardiac models [14, 15] was analogous
to our results in human renal vessels.
We also found a strong correlation between ET-1 stain-
ing in the neointima and progression of neointima growth
(that is, Russell index) and hypertension. The correlation
Table 4. Stimulation of ET-1 secretion by cytokines in human
endothelial and vascular smooth muscle cells in culture
Agonist
ET-1 secretion pg/well
HMCHUVEC VSMC
Control 21.3 6 5.1 2.5 6 0.7 12.7 6 1.5
IL-1b 10 ng/ml 52.6 6 6.8b 4.8 6 0.5b 24.9 6 3.2b
IL-6 10 ng/ml 34.7 6 6.3b 3.4 6 0.3a 38.5 6 2.8b
TNF-a 100 ng/ml 34.2 6 6.1b 3.1 6 0.7 ND
IL-2 10 ng/ml 19.9 6 3.4 2.3 6 0.6 9.3 6 2.8
IL-4 10 ng/ml 18.4 6 7.2 2.1 6 0.4 10.4 6 1.1
IFNg 100 ng/ml 22.7 6 3.0 2.6 6 0.7 13.6 6 1.7
TPA 100 nM 64.6 6 7.9b 3.7 6 0.5b 32.0 6 1.9b
HUVEC (human umbilical vascular endothelial cells), VSMC (vascular
smooth muscle cells), and HMC (human mesangial cells) in serum-free
medium were incubated with the indicated agonists for 5 hours at 37°C
before extraction of the supernatant and measurement of ET-1 levels by
ELISA as described in the Methods section. Data are mean 6 SEM, N 5
3 in duplicate.
a P , 0.05; b P , 0.01, ND, not determined
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between ET-1 staining and growth of the neointima is
suggestive of a mitogenic role for ET-1 in Tx-AA. Elevated
secretion of ET-1 in the neointima is not specific for Tx-AA
and has previously been shown in other diseases character-
ized by vascular neointima including atherosclerosis, coro-
nary artery restenosis, and hypertensive arterial remodeling
[3, 30, 31]. Although these correlations do not prove a
pathological role for ET-1, the correlation between ET-1
and hypertension is striking given the potent pressor ac-
tions of ET-1 and the prevalence of hypertension in
patients with chronic rejection. Results of another recent
study in human renal allograft recipients supports the
hypothesis that post-transplant diastolic hypertension is a
result of ET-1-mediated vasoconstriction [32]. The mecha-
nisms by which ET-1 might cause hypertension in these
patients has not been addressed in the present study.
However, ET-1 in humans has been shown to have a potent
antinatriuretic action that increases effective circulating
volume [33]. It is also possible that spillover of ET-1 into
the circulation might have a pressor effect similar to
mechanisms proposed for ET-1-induced hypertension in
other settings [31].
Another pathological hallmark of chronic renal allograft
rejection is Tx-AGS. In our studies ET-1 staining was also
elevated in Tx-AGS in a focal and segmental pattern. It
was, however, difficult to establish the precise staining
pattern in Tx-AGS and the increase over normal glomeru-
lar ET-1 staining (2.7-fold) was less than that for Tx-AA.
Mesangial hypercellularity and matrix expansion are com-
mon in Tx-AGS, and given the well-documented mitogenic
effects of ET-1 on mesangial cells it seems possible that
elevated ET-1 might contribute to the pathogenesis of
Tx-AGS. Further experiments are necessary to investigate
this hypothesis.
Fig. 5. Glomerular ET-1 staining is modestly
elevated in patients with Tx-AGS and chronic
rejection. Immunohistochemical staining for
ET-1 revealed a focal and segmental glomerular
localization (arrowheads) in Tx-AGS (A), which
contrasts with the primarily focal endothelial
localization (arrowheads) in normal kidney (B).
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Multiple cells express ET-1 in the neointima of Tx-AA
Previous experiments have shown that the neointima of
Tx-AA is a heterogeneous mixture of cell types including
endothelial cells, migrating vascular smooth muscle cells,
and lesser numbers of infiltrating macrophages and T cells
[1, 10]. Our present results confirm these studies in that the
neointima in renal Tx-AA was also populated with vascular
smooth muscle cells . endothelial cells 5 macrophages .
T cells. We also found a small percentage of immunohis-
tochemically unidentifiable cells, which has also been re-
ported in other studies [1]. The identity and source of these
cells is at present unknown. In our studies endothelial cells
were uniformly positive for ET-1 and T cells were negative.
In contrast, vascular smooth muscle cells and macrophages
displayed considerable heterogeneity in ET-1 staining: 35%
of vascular smooth muscle cells and 31% of macrophage/
monocytes elaborated ET-1. The reasons for this hetero-
geneity in ET-1 staining are unclear but might reflect
differences in activation state, phenotype, or cell cycle
phase.
The results of our experiments to identify ET-1-positive
cells in the neointima of Tx-AA are consistent with a recent
study in human cardiac allografts with chronic rejection in
which ET-1 staining was predominately in endothelial cells
and vascular smooth muscle cells with considerable heter-
ogeneity observed in macrophages [25]. However, our
findings differ somewhat from a previous study in rat
cardiac allografts in which mononuclear inflammatory cells
were the major cell type expressing ET-1 [14]. The reasons
for this apparent discrepancy are not clear but might reflect
differences in species and organ (human vs. rat and renal
vs. cardiac) or in the antibodies used to identify monocytes
Fig. 5. Cont’d. (C) Staining for Factor VIII
showed an intact glomerular endothelium
(arrowheads) in Tx-AGS. (D) Control staining
in Tx-AGS with non-immune serum.
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and macrophages (aCD-68 vs. aED-1). Most important,
however, all of the published studies document macro-
phage infiltration in the neointima of Tx-AA and point to
the potential importance of macrophages as a source of
ET-1 in Tx-AA.
Regulation of ET-1 secretion in Tx-AA
If elevated secretion of ET-1 is playing an important role
in neointima formation in Tx-AA, what might be possible
stimuli of ET-1 secretion by endothelial cells? In a rat
model of chronic renal allograft rejection, Tilney and
coworkers [16–18] have shown that T cell- and macro-
phage-derived cytokines are elevated immediately preced-
ing the sustained burst of ET-1 secretion. We therefore
asked whether T cell- or macrophage-derived cytokines
might stimulate ET-1 secretion in cultured human endo-
thelial cells. We found that macrophage-derived cytokines
IL-1b, IL-6, and TNF-a stimulated ET-1 secretion but that
IL-1b was considerably more active. The three T cell-
derived cytokines (IL-2, IL-4, IFNg) we tested were inac-
tive, which support a predominant role of macrophage-
derived cytokines to stimulate ET-1 secretion by
endothelial cells. It is interesting to speculate that the lack
of macrophage infiltration in renal veins might explain, in
part, the normal expression of ET-1 in the venous endo-
thelium in chronic rejection. Although it is sometimes
difficult to extrapolate results from cultured cells to the
same cells in vivo, Hancock et al [7] have previously
observed persistent and intense expression of IL-1b, IL-6,
and TNF-a in glomerular lesions of Tx-AGS. They pro-
posed that IL-6 in particular, which is a potent activator of
mesangial cells, might mediate mesangial expansion and
proliferation in Tx-AGS. It is therefore interesting that in
the present study IL-6 was identified as a potent stimulus of
ET-1 secretion for mesangial cells in culture. IL-6 was in
fact more potent than IL-1b in mesangial cells. Collectively
these results provide further evidence that IL-6 might be an
important mediator of Tx-AGS.
It is important to note, however, that our results do not
prove that macrophage-derived cytokines are the relevant
stimuli of ET-1 secretion by endothelial cells in Tx-AA. In
fact many other stimuli might contribute including throm-
bin, fluid mechanical shear stress, oxidized LDL, and the
persistent hypercholesterolemia observed in transplant re-
cipients receiving corticosteroids. Another confounding
factor is the ability of cyclosporine to stimulate ET-1
secretion in cultured endothelial cells and in intact kidney
[34, 35]. A role for ET-1 has also been shown in cyclospor-
ine-induced renal vasoconstriction and mesangial cell con-
traction [36–39]. But several lines of evidence appear to
contradict the notion that cyclosporine mediates the in-
crease of ET-1 in Tx-AA. First, in a cohort of 25 renal
allograft patients receiving cyclosporine but having stable
renal function, plasma ET-1 levels were normal and not
elevated as would be predicted if cyclosporine were stimu-
lating ET-1 secretion [40]. Second, in a previous study [21]
and in our present study renal transplant recipients with
acute rejection had normal or slightly lower levels of tissue
ET-1 despite receiving high doses of cyclosporine. Third,
and perhaps most impressive, in a rat model of chronic
cardiac allograft rejection that did not employ cyclosporine
or any other form of immunosuppresssion, ET-1 levels in
the neointima were still elevated [14]. Thus, the presence of
cyclosporine might not be necessary for enhanced ET-1
secretion, but it might certainly contribute in the presence
of other primary stimuli of ET-1 secretion.
In summary, the observations presented here, taken
together with earlier studies showing elevated ET-1 in
animal models of Tx-AA, suggest that increased secretion
of ET-1 might contribute to the abnormal growth of cells in
the neointima leading to Tx-AA and chronic rejection.
Since recent studies indicate that agents that antagonize
ET-1 actions might be of value in attenuating vascular cell
growth and neointima formation, it will be of interest to test
whether Tx-AA and chronic rejection can be improved by
therapies aimed at neutralization of ET-1.
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Fig. 6. Glomerular ET-1 is elevated in patients with Tx-AGS and chronic
rejection but not in patients with acute renal allograft rejection. Semi-
quantitative analysis of glomerular ET-1 peptide expression was per-
formed as described for Figure 2 with NIH Image in the same patients
with chronic and acute rejection described in Tables 1 and 2. Data are
mean 6 SEM.
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APPENDIX
Abbreviations used in this article are: DPBS, Dulbecco’s phosphate
buffered saline; ET-1, endothelin-1; HUVEC, human umbilical vein
endothelial cell; IFNg, interferon-g; IL, interleukin; TNF-a, tumor necro-
sis factor-a; TPA, 12–0–tetradecanoyl phorbol 13 acetate; Tx-AA, trans-
plantation-associated arteriosclerosis; Tx-AGS, transplantation-associated
glomerulosclerosis.
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